1. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses
- Author
-
Norio Hayashi, Masami Inada, Kiyoshi Mochizuki, Atsuo Inoue, Hiroyuki Fukui, Tsugiko Oze, Akinori Kasahara, M. Kato, Harumasa Yoshihara, Eiji Mita, Shinichi Kiso, Naoki Hiramatsu, A. Hohsui, Yasuharu Imai, Hideki Hagiwara, E. Hayashi, Yuko Inoue, Tatsuya Kanto, Takuya Miyagi, Tetsuo Takehara, Hisashi Ishida, Masahide Oshita, Shinji Tamura, and Takayuki Yakushijin
- Subjects
Adult ,Male ,medicine.medical_specialty ,Genotype ,Combination therapy ,Hepatitis C virus ,Alpha interferon ,Hepacivirus ,Interferon alpha-2 ,Pharmacology ,medicine.disease_cause ,Antiviral Agents ,Gastroenterology ,Polyethylene Glycols ,chemistry.chemical_compound ,Pharmacotherapy ,Pegylated interferon ,Virology ,Internal medicine ,Ribavirin ,medicine ,Humans ,Aged ,Hepatology ,Platelet Count ,business.industry ,Interferon-alpha ,virus diseases ,Hepatitis C ,Odds ratio ,Hepatitis C, Chronic ,Middle Aged ,Viral Load ,medicine.disease ,Recombinant Proteins ,digestive system diseases ,Treatment Outcome ,Infectious Diseases ,chemistry ,RNA, Viral ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
Summary. Reducing the dose of drug affects treatment efficacy in pegylated interferon (Peg-IFN) and ribavirin combination therapy for patients with hepatitis C virus (HCV) genotype 1. The aim of this study was to investigate the impact of drug exposure, as well as the baseline factors and the virological response on the treatment efficacy for genotype 2 patients. Two-hundred and fifty patients with genotype 2 HCV who were to undergo combination therapy for 24 weeks were included in the study, and 213 completed the treatment. Significantly more patients who achieved a rapid virological response (RVR), defined as HCV RNA negativity at week 4, achieved a sustained virological response (SVR) (92%, 122/133) compared with patients who failed to achieve RVR (48%, 38/80) (P
- Published
- 2010
- Full Text
- View/download PDF